



HAL
open science

A comment on Laboratory monitoring of new anticoagulants

Bernardo Cortese

► **To cite this version:**

Bernardo Cortese. A comment on Laboratory monitoring of new anticoagulants. American Journal of Hematology, 2010, 85 (7), pp.546. 10.1002/ajh.21718 . hal-00552322

HAL Id: hal-00552322

<https://hal.science/hal-00552322>

Submitted on 6 Jan 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



A comment on Laboratory monitoring of new anticoagulants

| | |
|-------------------------------|--|
| Journal: | <i>American Journal of Hematology</i> |
| Manuscript ID: | AJH-10-0095.R1 |
| Wiley - Manuscript type: | Correspondence |
| Date Submitted by the Author: | 04-Mar-2010 |
| Complete List of Authors: | Cortese, Bernardo; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Cardiologic |
| Keywords: | Anticoagulation therapy |
| | |



view

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A comment on Laboratory monitoring of new anticoagulants

Bernardo Cortese, MD, FESC

Division of Cardiology,

Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico,

Via F. Sforza, 35

Milano, Italy.

E-mail: bcortese@gmail.com

Tel : +39 02 55033532

Fax: +39 02 55033530

Disclosures: none.

Word count: 499.

Formatted: Font color: Auto

For Peer Review

1
2 To the Editor: In their recent paper, D.D. Castellone and E.M. Van Cott review recent
3 developments in laboratory and bedside testing for some of the newest anticoagulants [1].

4 This review is a clear and easily understandable tool for clinicians, which provides a
5 comprehensive summa of available and lesser available laboratory tests for their preferred
6 anticoagulants (both factor IIa or factor Xa inhibitors).
7

8 However, I would like to expand on bivalirudin management in the cardiovascular area.
9

Formatted: Not Highlight

Formatted: Not Highlight

Formatted: Not Highlight

10
11
12
13
14
15 Bivalirudin is a synthetic polypeptide that binds to an active site of thrombin, blocking it; it
16 has a short half-life (20-25 minutes) and only 20% of it is renally excreted.

17
18
19 This drug is currently indicated for the management of patients suffering acute coronary
20 syndromes undergoing coronary angioplasty and for patients undergoing elective
21 angioplasty. It is also indicated for patients with (or at risk for) heparin induced
22 thrombocytopenia undergoing PCI (U.S.A.).
23
24
25
26
27

28
29 Regarding drug monitoring, the authors state that the aPTT monitoring is currently
30 adopted; however, they state, this test is not ideal due to inaccuracy at high drug dosages.
31
32 The authors conclude that a more precise evaluation of the anticoagulant effect of
33 bivalirudin could be achieved with complex laboratory tests, such as the chromogenic anti-
34 factor IIa assay, or the Ecarin Clotting Time.
35
36
37
38

39
40 In the catheterization laboratory, unlike unfractionated heparin which needs frequent
41 monitoring of activity and is usually given with multiple intravenous boluses, bivalirudin is
42 given with a bolus dose of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h for the
43 duration of the procedure and possibly with a further infusion of 0.25 mg/Kg/h for 4 hours
44 following the angioplasty (the prolonged infusion after PCI has been approved in Europe
45 and has shown to reduce the risk and extent of peri-procedural myocardial infarction) [2].
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Otherwise, the USA/FDA approved package insert also says that “Continuation of the
3 Angiomax infusion following PCI for up to 4 hours post-procedure
4 is optional, at the discretion of the treating physician. After 4 hours, an additional IV
5 infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours, if
6 needed.” That’s all. No further monitoring is needed with this drug, because if its activity
7
8 on laboratory monitoring (e.g., the aPTT or the Activated Clotting Time) is unpredictable,
9
10 its biological and clinical activity is reliable. In fact, bivalirudin has been shown to exert an
11
12 antithrombotic efficacy comparable to that of heparin with or without glycoprotein IIb/IIIa
13
14 inhibitors, warranting fewer bleedings [3, 4].

15
16 In case of hemorrhages the infusion should be interrupted because an antidote is not
17
18 available and its half life is short. Bivalirudin is hemodialyzable. Activated Clotting Time
19
20 monitoring is --preferable only in patients with renal impairment, where bivalirudin’s half life
21
22 is prolonged. In case of severe renal impairment (hemodialysis or creatinine clearance <30
23
24 ml/min) it is contraindicated (Europe).

25
26 Therefore, in my opinion, the highly predictable biological effect and the safety of this drug
27
28 render its monitoring unnecessary (and too expensive), at least in the vast majority of
29
30 patients undergoing coronary angioplasty.

31 32 33 34 35 36 37 38 39 40 REFERENCES

- 41
42 1. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J
43 Hematol 2010;85:185-187.
- 44
45 2. Cortese B, Picchi A, Micheli A, et al. Comparison of prolonged bivalirudin infusion
46 versus intraprocedural in preventing myocardial damage after percutaneous
47
48
49

Formatted: No underline, Font color: Auto

1
2 [coronary intervention in patients with angina pectoris. Am J Cardiol](#)
3
4 [2009;104\(8\):1063-1068.](#)

Formatted: Font color: Auto

5
6 3. [Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary](#)
7
8 [syndromes. N Engl J Med 2006;355: 2203–2216.](#)

Formatted: Font color: Auto

9
10 4. [Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin](#)
11
12 [during percutaneous coronary intervention. N Engl J Med 2008;359:688-696.](#)

Formatted: Font color: Auto

Formatted: Font color: Auto

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review